EUVIMEDEUVIMED entdecken
Crossref

The ameliorative effects of topical gemifloxacin alone or in combination with clobetasol propionate on imiquimod-induced model of psoriasis in mice

Hayder Ridha Salman iD, Adeeb Ahmed Al-Zubaidy, Alaa Hamza Abbas, Qassim A Zigam iD

Naunyn-Schmiedeberg's Archives of Pharmacology · 2024

DOI: 10.1007/s00210-023-02629-9 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Naunyn-Schmiedeberg's Archives of Pharmacology, 2024. Verfasst von Hayder Ridha Salman und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacology, College of Pharmacy, Al-Mustaqbal University, 510001, Hillah, Babylon, Iraq. hayder80.ridha@gmail.com. Hauptthemen laut MEDLINE: Clobetasol, Psoriasis. Die Arbeit wurde bisher 28-mal zitiert (Crossref) und nennt 124 Literaturangaben. Gefördert von: Self Funding By corresponding author.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Psoriasis is a lifelong immune-driven skin condition characterized by excessive epidermal overgrowth and inflammatory cell infiltration. Gemifloxacin is a fourth-generation fluoroquinolone with improved immunomodulatory and anti-inflammatory properties that are believed to possess an attractive role in psoriasis via suppressing the production of cytokines, chemokines, and eosinophil and neutrophil chemotaxis. The aim of this research is to investigate the ameliorative effects of prolonged topical gemifloxacin (GMF) alone and combined with clobetasol propionate (CLO) on an imiquimod (IMQ)-induced mouse model of psoriasis. Forty-eight Swiss albino mice were divided into six groups of eight. All groups except the negative controls got 62.5 mg of IMQ 5% topically for 8 days. Mice in the control group (controls) got Vaseline instead. Following the induction in the IMQ 5% group, mice in treatment groups CLO 0.05, GMF 1%, GMF 3%, and CLO + GMF obtained clobetasol propionate 0.05%, GMF 1% and 3%, and a combination of both, respectively, for an additional 8 days, rendering the experiment 16 days long. Our results revealed that gemifloxacin alleviated erythematous, thickened, and scaly psoriatic lesions and inhibited the tissue level of inflammatory cytokines, including interleukin (IL)-8, IL-17A, IL-23, tumor necrosis factor-α (TNF-α), and transforming growth factor-β1 (TGF-β1). The anti-inflammatory effect also occurred by hindering nuclear factor-kappa B (NF-κB) signaling and reversing histopathological problems. Gemifloxacin acts effectively in mitigating psoriasis-associated lesions and restricting NF-κB-mediated inflammation, recommending gemifloxacin as a promising adjuvant candidate for additional studies on the long-term treatment of autoimmune and autoinflammatory dermatoses like psoriasis.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

ClobetasolPsoriasisAnimalsMiceImiquimodGemifloxacinNF-kappa BGlia Maturation FactorSkinCytokinesAnti-Inflammatory AgentsDisease Models, AnimalMice, Inbred BALB C

Stichwörter der Autor:innen

Animal models of psoriasisExperimental dermatologyExperimental pharmacologyFluoroquinolonesGemifloxacinImiquimod-induced psoriasisImmune-mediated diseasesInflammatory skin diseasesPsoriasis treatmentTopical drug formulation

Substanzen

ImiquimodClobetasolGemifloxacinNF-kappa BGlia Maturation FactorCytokinesAnti-Inflammatory Agents

Autor:innen und Institutionen

  • Department of Pharmacology, College of Pharmacy, Al-Mustaqbal University, 510001, Hillah, Babylon, Iraq. hayder80.ridha@gmail.com.
  • Department of Pharmacology, College of Medicine, Al-Nahrain University, Baghdad, Iraq. hayder80.ridha@gmail.com.
  • Department of Pharmacology, College of Medicine, University of Warith Al-Anbiyaa, Karbala, Iraq.
  • Department of Pharmacology, College of Medicine, Al-Nahrain University, Baghdad, Iraq.
  • Department of Pharmacology, College of Pharmacy, Al-Mustaqbal University, 510001, Hillah, Babylon, Iraq.

ORCID-Profile: Hayder Ridha Salman, Qassim A Zigam

Förderung

  • Self Funding By corresponding author

Zitieren

APA

Salman, H. R., Al-Zubaidy, A. A., Abbas, A. H., & Zigam, Q. A. (2024). The ameliorative effects of topical gemifloxacin alone or in combination with clobetasol propionate on imiquimod-induced model of psoriasis in mice. Naunyn-Schmiedeberg's Archives of Pharmacology. https://doi.org/10.1007/s00210-023-02629-9

Vancouver

Salman HR, Al-Zubaidy AA, Abbas AH, Zigam QA. The ameliorative effects of topical gemifloxacin alone or in combination with clobetasol propionate on imiquimod-induced model of psoriasis in mice. Naunyn-Schmiedeberg's Archives of Pharmacology. 2024. doi:10.1007/s00210-023-02629-9

BibTeX
@article{Salman2024,
  author = {Salman, Hayder Ridha and Al-Zubaidy, Adeeb Ahmed and Abbas, Alaa Hamza and Zigam, Qassim A},
  title = {The ameliorative effects of topical gemifloxacin alone or in combination with clobetasol propionate on imiquimod-induced model of psoriasis in mice},
  journal = {Naunyn-Schmiedeberg's Archives of Pharmacology},
  year = {2024},
  doi = {10.1007/s00210-023-02629-9}
}
Kostenlos starten →